
Jenburkt Pharmaceuticals Downgraded to Sell Amid Technical Weakness and Flat Financials
2026-11-19 08:03:05Jenburkt Pharmaceuticals Ltd has seen its investment rating downgraded from Hold to Sell as of 18 Nov 2026, reflecting a deterioration in technical indicators despite an attractive valuation and stable financial metrics. The downgrade is driven primarily by a shift to bearish technical trends, while valuation metrics have improved, and financial performance remains flat. This comprehensive analysis explores the four key parameters influencing the rating change: Quality, Valuation, Financial Trend, and Technicals.
Read More
Jenburkt Pharmaceuticals Upgraded to Hold on Improved Valuation and Technicals
2026-11-16 08:03:11Jenburkt Pharmaceuticals Ltd has seen its investment rating upgraded from Sell to Hold, driven primarily by improvements in technical indicators and a more attractive valuation profile. Despite recent flat financial performance and underwhelming returns over the past year, the company’s solid management efficiency and net-debt-free status underpin a cautiously optimistic outlook.
Read MoreJenburkt Pharmaceuticals Gains 10.42%: 2 Key Factors Driving the Weekly Rally
2026-11-08 16:00:46Key Events This Week 2 Nov: Stock hits 52-week low at Rs.848.05 3 Nov: Sharp rebound with 4.65% gain to Rs.900.00 5 Nov: Valuation upgrade signals renewed price attractiveness 6 Nov: Week closes at Rs.943.00, up 10.42% for the week Week OpenRs.854.00 Week CloseRs.943.00<div class="stat-ch...
Read More
Jenburkt Pharmaceuticals Ltd: Valuation Shifts Signal Renewed Price Attractiveness
2026-11-05 08:00:20Jenburkt Pharmaceuticals Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating. This change reflects a more compelling price point relative to its historical averages and peer group, despite the company’s mixed recent returns compared to the broader Sensex index.
Read More
Five Consecutive Losses Push Jenburkt Pharmaceuticals Ltd to a New 52-Week Low
2026-10-30 12:35:05For the fifth straight session, Jenburkt Pharmaceuticals Ltd closed lower, breaching its 52-week low at Rs 848.35 on 30 Oct 2026. This decline comes amid a backdrop of underwhelming financial performance and persistent selling pressure, despite the broader market showing signs of resilience.
Read More
Jenburkt Pharmaceuticals Ltd is Rated Sell by MarketsMOJO
2026-10-29 10:10:02Jenburkt Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 7 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 October 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read More
Five Consecutive Losses Push Jenburkt Pharmaceuticals Ltd to a New 52-Week Low
2026-10-22 13:40:04For the fifth consecutive session, Jenburkt Pharmaceuticals Ltd has closed lower, hitting a fresh 52-week low of Rs 867.5 on 22 Oct 2026, marking a 6.01% decline over the last two days alone.
Read More
Jenburkt Pharmaceuticals Ltd is Rated Sell
2026-10-17 10:10:05Jenburkt Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 7 August 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 17 October 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
04-Nov-2026 | Source : BSENewspaper Publication for standalone Unaudited financial results for the quarter and half year ended on 30th September 2026.
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
04-Nov-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Counter Cyclical Investment Pvt Ltd
Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026
03-Nov-2026 | Source : BSEStandalone Unaudited Financial Results for the quarter and half year ended on 30th September 2026.
Corporate Actions
No Upcoming Board Meetings
Jenburkt Pharmaceuticals Ltd has declared 207% dividend, ex-date: 28 Aug 26
No Splits history available
No Bonus history available
No Rights history available
